<DOC>
	<DOC>NCT01774604</DOC>
	<brief_summary>The purpose of this study is to assess whether peri-procedural administration of rectal indomethacin, compared to placebo, can reduce the incidence of post-ERCP pancreatitis.</brief_summary>
	<brief_title>Rectal Indomethacin to Prevent Post-Endoscopic Retrograde Cholangiopancreatography (ERCP) Pancreatitis</brief_title>
	<detailed_description />
	<mesh_term>Pancreatitis</mesh_term>
	<mesh_term>Indomethacin</mesh_term>
	<criteria>1. Scheduled for an ERCP at DartmouthHitchcock 2. Age greater than 18 years old 3. Ability to provide written informed consent 1. Inability to provide written informed consent 2. ERCP being performed for diagnosis and/or treatment of acute pancreatitis 3. Current ongoing acute pancreatitis 4. Previously documented allergy to NonSteroidal AntiInflammatory Drugs (NSAIDs) 5. Contraindication to NSAID therapy (creatinine level &gt;1.4 or active peptic ulcer disease), already taking NSAIDs (other than aspirin therapy for cardioprotection) 6. Pregnant or nursing mothers</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Post ERCP acute pancreatitis</keyword>
	<keyword>Post Fine Needle Aspiration (FNA) acute pancreatitis</keyword>
	<keyword>Indomethacin</keyword>
	<keyword>Rectal Non Steroidal Anti-Inflammatory Drugs (NSAIDs)</keyword>
</DOC>